

# Theodora Hatziioannou

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6170729/theodora-hatziioannou-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

7,870

citations

32

h-index

79

g-index

79

ext. papers

11,951

ext. citations

24.9

avg, IF

6.32

L-index

#	Paper	IF	Citations
68	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. <b>2022,</b>		1
67	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. <b>2022,</b>		3
66	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. <i>Immunity</i> , <b>2022,</b>	32.3	10
65	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , <b>2022,</b>	50.4	14
64	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. <i>New England Journal of Medicine</i> , <b>2021,</b>	59.2	93
63	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. <b>2021,</b>		31
62	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , <b>2021,</b> 10,	8.9	3
61	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , <b>2021,</b>	50.4	69
60	Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , <b>2021,</b> 374, 1099-1106	33.3	7
59	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , <b>2021,</b> 22, 1503-1514	19.1	12
58	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , <b>2021,</b> 218,	16.6	171
57	Evolution of Antibody Immunity to SARS-CoV-2 <b>2021,</b>		43
56	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. <i>Clinical Infectious Diseases</i> , <b>2021,</b> 73, e1208-e1211	11.6	37
55	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies <b>2021,</b>		24
54	Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants <b>2021,</b>		8
53	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , <b>2021,</b> 593, 424-428	50.4	36
52	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies <b>2021,</b>		27

51	Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2 <b>2021</b> ,		4
50	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies <b>2021</b> ,		13
49	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year <b>2021</b> ,		19
48	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , <b>2021</b> , 595, 426-431	50.4	247
47	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , <b>2021</b> , 595, 278-282	50.4	49
46	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2212-2218	59.2	347
45	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009688	7.6	7
44	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity <b>2021</b> ,		2
43	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , <b>2021</b> , 12, 4196	17.4	106
42	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 389-398	7	136
41	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	178
40	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , <b>2021</b> , 591, 639-644	50.4	652
39	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease <b>2021</b> ,		2
38	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , <b>2021</b> , 592, 616-622	50.4	730
37	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , <b>2021</b> , 54, 1853-1868.e7	32.3	83
36	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , <b>2021</b> , 36, 109760	10.6	29
35	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland.. <i>Journal of Clinical Virology Plus</i> , <b>2021</b> , 1, 100028		
34	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , <b>2021</b> ,	50.4	65

33	A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques <b>2021</b> ,		1
32	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants <b>2021</b> ,		54
31	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100164	18	14
30	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , <b>2020</b> , 182, 828-842.e16	56.2	485
29	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , <b>2020</b> , 9,	8.9	784
28	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants <b>2020</b> ,		31
27	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies <b>2020</b> ,		30
26	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients <b>2020</b> ,		30
25	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants <b>2020</b> ,		32
24	Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents <b>2020</b> ,		37
23	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro <b>2020</b> ,		15
22	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection <b>2020</b> ,		21
21	Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection <b>2020</b> ,		12
20	A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques <b>2020</b> ,		1
19	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , <b>2020</b> , 584, 437-442	50.4	1167
18	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	289
17	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10504-10509	11.5	6
16	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007632	7.6	9

15	Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	5
14	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. <i>ELife</i> , <b>2019</b> , 8,	8.9	4
13	A single gp120 residue can affect HIV-1 tropism in macaques. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006572	7.6	20
12	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3413-22	11.5	132
11	Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. <i>Cell Host and Microbe</i> , <b>2014</b> , 16, 412-8	23.4	41
10	HIV-1-induced AIDS in monkeys. <i>Science</i> , <b>2014</b> , 344, 1401-5	33.3	61
9	MX2 is an interferon-induced inhibitor of HIV-1 infection. <i>Nature</i> , <b>2013</b> , 502, 563-6	50.4	337
8	Assisted evolution enables HIV-1 to overcome a high TRIM5 $\alpha$ -imposed genetic barrier to rhesus macaque tropism. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003667	7.6	24
7	Animal models for HIV/AIDS research. <i>Nature Reviews Microbiology</i> , <b>2012</b> , 10, 852-67	22.2	208
6	A macaque model of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 4425-9	11.5	124
5	Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. <i>Cell Host and Microbe</i> , <b>2009</b> , 6, 409-21	23.4	339
4	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3563-8	11.5	159
3	Generation of simian-tropic HIV-1 by restriction factor evasion. <i>Science</i> , <b>2006</b> , 314, 95	33.3	123
2	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
1	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7